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Abstract 
Non-medical use of prescription drugs (NMUPD) is increasing among the general population, 
and particularly among teenagers and young adults. Although prescription drugs are considered 
as safer than illicit street drugs, NMUPD can lead to detrimental consequences. The aim of the 
present study was to investigate the relationship between drug use (NMUPD on the one side, 
illicit street drugs on the other side) with mental health issues, and to compare these associations. 
A representative sample of 5,719 young Swiss men aged around 20 filled in a questionnaire as 
part of the baseline ongoing Cohort Study on Substance Use Risk Factors (C-SURF). Drug use 
(16 illicit street drugs and 5 NMUPD: sleeping pills, sedatives, pain killers, antidepressants, 
stimulants) and mental health issues (depression, SF12) were assessed. Simple and multiple 
linear regressions were used. In simple regressions, all illicit and prescription drugs were 
associated with a poorer mental health. In multiple regressions, most of the NMUPD were 
significantly associated with a poorer mental health, excepted for stimulants and anxiolytics with 
depression. On the contrary, the only associations that remain significant between illicit street 
drugs and mental health involved cannabis. NMUPD is of growing concern not only because of 
its increasing occurrence, but also because of its association with depression and mental health 
problems, which is stronger than the association observed between these problems and illicit 
street drug use, excepted for cannabis. Therefore, NMUPD need to be considerate in screening 
for substance use preventive purposes. 
 
Key words: Depression; Illicit street drug; Mental health; Non-medical use of prescription drug. 
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Introduction 
Prescription drugs are fundamental to the treatment of pain and psychiatric disorders such as 
depression or anxiety. Unfortunately, they can also cause abuse and dependency (1, 2) and this 
kind of use constitutes a critical public health concern (3).  Non-medical use of prescription 
drugs (NMUPD) has been defined as the use of a prescription drug i) without a doctor’s 
prescription; ii) for a longer period than prescribed; iii) for other reasons than those for which it 
was prescribed; or iv) in doses higher than those recommended (3-5). The purpose of use can be 
recreational (getting high, euphoric or intoxicated) or self-medication (5-7). Most studies took 
place in the United States, and no comparison with other drug use was investigated. This study 
compared NMUPD and illicit street drugs in Switzerland. 
 
NMUPD is of growing concern for several reasons. First, NMUPD has been shown in the United 
States to be the the second most common type of drug use after marijuana among teenagers and 
young adults (8-10). Second, NMUPD is increasing, particularly among young populations (11). 
For example, NMUPD increased by 67% in the USA between 1991-1992 and 2001-2002 (12), 
and is growing faster than marijuana use (10, 13). So NMUPD did not seem to be used only 
among heavy substance users. Third, prescription drugs are easier to obtain than illicit street 
drugs (14, 15). People also tend to think that prescription drugs are safer than illicit street drugs 
(7, 14, 16)., but many studies which looked at the association between NMUPD and mood or 
personality disorders showed that NMUPD is associated with  detrimental effects such as 
cognitive deficit, mood disorders such as depression, accidental overdoses, psychiatric disorders, 
but also physical problems such as organ damage, and other substance use disorders (2, 12, 15-
22). These results seemed to be inconsistent with the belief that NMUPD are safer than illicit 
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street drugs and that prescription drugs are not “really drugs” (23). However, no study compared 
the the associations of NMUPD and mental health issues with the one of the associations of illicit 
street drugs and mental health issues. 
 
Therefore, the aim of this study was to investigate the relationship between drug use (illicit street 
drugs and NMUPD) and mental health issues (depression and mental health problems, i.e. 
sadness, nervousness and depression). We aimed to find out which association was higher. A 
total of 16 illicit street drugs including cannabis and 5 type of NMUPD (sleeping pills, sedatives, 
pain killers, antidepressants, and stimulants) were analyzed. Moreover, this study aimed to 
provide further insights regarding NMUPD in an other country (Switzerland) than the U.S. and 
Canada, where most previous studies have been conducted (15). 
 
Methods 
Sample and data collection 
The data used in this study form part of the Cohort Study on Substance Use Risk Factors (C-
SURF). C-SURF is a longitudinal study which takes place in Switzerland and is designed to 
assess substance use patterns and related consequences in Swiss young men. Illicit drug use, 
NMUPD and mental health issues were collected at the same time during the baseline assessment 
of the C-SURF study. Enrolment took place between August 23, 2010 and November 15, 2011 at 
three (of six) army recruitment centers located in Lausanne (French-speaking) and Windisch and 
Mels (German-speaking). These centers cover 21 of 26 cantons in Switzerland, including all 
French-speaking cantons. In Switzerland, army recruitment is mandatory, so the study was 
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largely representative of all young Swiss men. The study got ethical approval by the Ethics 
Committee for Clinical Research of the Lausanne University Medical School and followed the 
Helsinki declaration. 
 
Altogether, of the 13,245 conscripts informed about the study, 7,563 gave written consent to 
participate and 5,990 filled in the baseline questionnaire. Missing values were listwise deleted, so 
the study ultimately included 5,719 participants (95.5% of the sample). More information about 
sampling and non-response can be found in Studer et al. (24). Shortly non-respondents were 
more often substance users, but the differences between respondent’s and non-respondents were 
small and may be significant only because of the large sample size. 
 
Measures 
Participants who consented to participate were invited by mail or email to fill in a paper and pen 
or an online questionnaire, according to the favorite way they indicated in the written consent. 
The questionnaire lasted approximately 1 hour and included topics such as sociodemographic 
background, health, family background, substance use (alcohol, tobacco, cannabis, other illicit 
drugs, NMUPD), personality and leisure time activities and sexuality. Participants answered first 
health issues, and then substance use. 
NMUPD. NMUPD was assessed with five questions about the use of prescription drugs without 
a doctor’s prescription or for reasons other than those indicated during the past 12 months. The 
answers were collected on a 8-point scale (never, once, 2-3 times a year, 4-9 times a year, 1-2 
times a month, 3-4 time a month, 2-3 times a week and 4 times a week or more) and coded 
dichotomously as “used” or “not used”. The prescription drugs and associated examples were as 
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follows: i) sleeping pills (e.g., benzodiazepine (Dalmadorm®, Rohypnol®, Halcion®), 
barbiturate, chloralhydrate (Nervifène®), zopiclon, zolpidem (Imovane®, Stilnox®)); ii) 
tranquilizers (e.g., benzodiazepine (Valium®, Xanax®, Librax®, Temesta®, Normison®, 
Demetrin®, Dalmadorm®) and muscle relaxing drugs); iii) strong painkillers (e.g., 
buprenorphine (Tamgesic®), codeine (Benylin®), opium-based products (Fentanyl®, 
Hydrocodon®, Jurnista®, Palladon®, Targin®, Oxycontin®, Vicodin®, Dilaudid®) and DXM 
(Bexin®); but over-the-counter painkillers such as Aspirin® and Paracetamol® were excluded); 
iv) antidepressants (Remeron®, Fluoxetine®, Citalopram®, Trimin®); and v) stimulants (e.g. 
amphetaminsulphate (Aderall®), atomoxetine (Strattera®), methylphenidate (Ritalin®)).  
 
Illicit street drugs. The prevalence rate of illicit street drugs during the past 12 months was 
measured for 16 drugs. The drugs were as follows: i) cannabis (hashish, marihuana, grass); ii) 
hallucinogens, magic mushrooms, psilocybin, peyote, mescaline; iii) other hallucinogens (LSD, 
PCP/Angeldust, 2-CB, 2-CI); iv) salvia divinorum; v) speed; vi) amphetamine, 
methamphetamine, amphetaminsulfate (e.g., Dexedrine, Benzedrin); vii) crystal meth (Ice); viii) 
poppers (Amylnitrit, Butylnitrit); ix) solvent sniffing (e.g., glue, solvent and gas such as benzin, 
ether, toulol, trichloräthylen, nitrous oxide); x) ecstasy, MDMA; xi) cocaine, crack, freebase; xii) 
heroin; xiii) ketamine (Special K), DXM; xiv) GHB / GBL / I-4 Butandiol (BDB); xv) research 
chemicals used in research (e.g., mephedrone, butylone and methedrone); and xvi) spices or 
similar substances (synthetic marijuana). The drugs were aggregated in 5 subclasses: 1) 
cannabis; 2) hallucinogens, including magic mushrooms, other hallucinogens, salvia divinorum 
and spice; 3) uppers, including speed, ecstasy, cocaine and amphetamine; 4) sniffed drugs, 
including poppers and solvents; 5) “hard” drugs, including crystal meth, heroin, ketamine and 
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chemicals used in research. Each subclass was collected on a 3-point scale (never, 1-3 times, 4 
times or more) and coded dichotomously “used” or “non-used”. 
Participants indicated first their illicit street drug use, and then their NMUPD. 
 
Mental health issues. Mental health issues were assessed with depression and mental health 
problems. The Major (ICD-10) Depressive Inventory (WHO-MDI) was used to determine the 
level of depression (25, 26). It comprises 10 criteria, with two criteria being assessed by two 
questions (restless vs. subdued and increased vs. reduced appetite, where the higher score of the 
two alternatives for each criterion was used). A six-point scale from “never” (0) to “all the time” 
(5) was used, and a total score from 0 to 30 was computed (Cronbach’s α = .91). Mental health 
was assessed with six questions from the 12-items Short-Form Health Survey (SF-12) (SF-12; 
27) dealing with sadness, nervousness and depression. The total score was computed according 
to the authors’ recommendations (with a standardized mean of 50, with lower values reflecting a 
bad mental health, Cronbach’s α = .61). Participants completed first SF12, and then WHO-MDI. 
 
Covariates. Demographic covariates included language (French- or German-speaking), 
urbanicity (urban area: more than 10,000 inhabitants; rural area: less than 10,000 inhabitants), 
perceived family income (“below-average income”, “average income”, “above-average income”) 
and completed education (primary: 9 years of schooling; secondary: around 12 years; tertiary: 13 
years or more, including university). 
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Statistical analyses 
First, descriptive statistics were computed to investigate the prevalence rate of NMUPD. Linear 
regressions were then performed to test the relationship between drug use and mental health 
issues, comparing illicit street drugs and NMUPD’s associations with mental health issues. 
Depression and mental health were considered successively as outcome variables and illicit street 
drug and non-medical prescription drug use as dichotomic exposure variables. Simple linear 
regressions were performed for each of the 5 subclasses if illicit street drugs and 5 NMUPD for 
the 2 outcome variables, and then multiple linear regressions including all the illicit and NMUPD 
were performed for the 2 outcome variables. Multicollinearity was checked to avoid reducing the 
predictive power of the model. Simple and multiple regressions were performed to test the 
individual and combined influence of each drug on mental health and to isolate the relationship 
between each drug used and mental health, accounting for the other drugs. Indeed, one can 
suppose that the drugs share common variance and this covariance should be taken into account 
to reflect properly the relationship between drug use and mental health. All the models were 
tested with adjustment for demographic variables (adjusted models). Standardized regression 
slopes (β) were presented instead of raw slopes to permit comparability between different drugs 
(illicit street drugs and NMUPD) with a scale-free estimation (28). The standardized slope could 
be considered as an effect-size index (28). A Bonferroni-Holms correction was performed in 
post-hoc comparisons to keep the type I error rate at 5%. All the analyses were conducted with 
SPSS 20. 
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Results 
Preliminary results 
The participants’ mean age was 20.0 years (SD: 1.23), 55.0% were French-speaking and 41.1% 
lived in urban areas. Most participants had completed primary education (48.4%, secondary: 
26.0%; tertiary or higher: 25.5%) and only 14.3% had a family income below average (average: 
41.5%; above average: 44.1%). The average level of depression was low (mean = 7.0, SD = 7.2) 
as the average level of mental health problems (mean = 47.4, SD = 9.1). 
The prevalence rates of drug use are illustrated in Table 1. The most prevalent illicit street drugs 
were cannabis (30.3%), then uppers (5.6%) and hallucinogens (5.0%). The most prevalent non-
medical prescription drugs were painkillers (6.8%), then sleeping pills (3.0%) and anxiolytics 
(2.6%). Stimulants and antidepressants were less prevalent (1.9% and 0.9%, respectively).  
 
Please insert Table 1 about here 
 
Associations of mental health issues with NMUPD and illicit street drugs 
The simple regressions showed that all the drugs were significantly associated with mental health 
issues (see Table 2). The use of the drug considered during the past 12 months was associated 
with a poorer mental health (increased depression, coefficients range between .080 and .163; 
decreased mental health, coefficients range between -.056 and -.131). 
 
Please insert Table 2 about here 
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In multiple regressions, the comparisons showed that cannabis, sleeping pills, painkillers, 
antidepressants and anxiolytics were significantly associated with mental health issues (excepted 
for anxiolytics with SF12), whereas other illicit street drugs were never significantly associated 
with mental health issues (see Table 3). Participants who reported higher levels of depression or 
mental health problems were more likely to be cannabis and non-medical prescription drugs 
users, with the exception of stimulants, which were not associated with mental health. Mental 
health was not significantly associated with any other illicit street drug. 
 
Please insert Table 3 about here 
 
Discussion 
Main findings 
This study compared the associations of NMUPD and illicit street drug use with mental health 
issues (depression and mental health problems) within a sample of young Swiss men, and tried to 
find out if one of these two kinds of drugs was associated with increased mental health issues. It 
also provided further insights regarding NMUPD in countries other than the U.S. and Canada, 
where NMUPD has been most studied. 
 
The prevalence rate for NMUPD and illicit street drug use during the previous 12 months 
indicated that cannabis was by far the most common drug used by the participants (30.3%). The 
second most used substance was painkillers (6.8%). This result is in accordance with previous 
studies that reported painkillers to be the most common NMUPD (15, 29-31), after cannabis use. 
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The new epidemic observed in North America may then also affect Switzerland. Calming 
prescription drugs were more prevalent than stimulants (sleeping pills: 3.0%, anxiolytics: 2.6%), 
as was found in the U.S. in the “Monitoring the Future” study (31). In contrast, the most 
prevalent illicit street drugs other than cannabis were stimulants (5.6%) and hallucinogens 
(5.0%). Downers seemed to be more popular among prescription drugs and uppers among illicit 
street drugs.  
 
Mental health issues were found to be differently associated with drug use when simple or 
multiple regressions were performed. Im simple regression, the use of each substance was 
associated with a poorer mental health. However, when multiple regressions were performed, the 
only significant associations were for cannabis and NMUPD (excepted stimulants for depression 
and SF12, and anxiolytics for SF12). Cannabis use and NMUPD wer associated with higher level 
of mental health problems and depression than non-cannabis use or non-NMUPD. That is to say, 
the illicit street drugs other than cannabis and prescription stimulants showed no longer 
detrimental associations with mental health when their common variance with cannabis and 
NMUPD was eliminated. Even if illicit drugs other than cannabis were individually associated 
with a poorer mental health, when all the substances were combined, cannabis and NMUPD 
were sufficient to explain the relationship between drug use and mental health, as the remaining 
and proper variance of illicit drugs other than cannabis was not significantly associated with 
mental health issues. The result was true even for the “hardest” illicit street drugs, including 
heroin, ketamine or crystal meth. Previous studies reported that users think that prescription 
drugs are safer than illicit street drugs (7, 14, 16), and the results highlighted in this study 
showed it was not the case. Interestingly, prescription stimulants showed a similar pattern as 
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illicit street drugs. It suggested that prescription stimulants should be used similarly as illicit 
street drugs, whereas downers NMUPD were not. Maybe prescription stimulants and illicit street 
drugs were used to get high and in recreational purpose, whereas downers NMUPD were used in 
a coping way. However, more studies are needed, as motives of use were not investigated in the 
current study. Cannabis was the only illicit street drug that showed significant associations with 
mental health issue. Previous findings showed that cannabis is harmful to health (32), and the 
result of this study, even it did not access a causal relationship between cannabis use and mental 
health, is especially worrying as cannabis is the most used illicit drug worldwide (33, 34). 
 
Limitations 
This study presents several limitations. The most critical is that this cross-sectional study did not 
allow determination of causality: is NMUPD a cause or a consequence of mental health issues? 
This is a common limitation in studies on drug use (5, 16, 35). For example, antidepressants may 
be overused by people who are already depressed, so NMUPD may be a consequence of 
depression and not a cause. However, irregular use of antidepressants is also associated with 
worsening depression (36, 37). Another limitation is the similarity between mental health issues 
and intoxication symptoms. Indeed, many symptoms of intoxication resemble the symptoms of 
mood disorders (8). It can be difficult to distinguish between “real” mental health issues and the 
effects of heavy use of non-medical prescription drugs. Nevertheless, the participants in our 
study were not heavy users. 
Regarding stimulants, both illicit street drugs and prescription stimulants included similar 
components (for example, Dexedrine). Therefore, confusion may have occurred for these two 
subclasses of substances.  
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We do not know whether prescription drugs were used by our participants to get high or as self-
medication. Further research is needed to highlight the prevalence rate and effect of NMUPD in 
relation to reasons for this use, and to investigate the difference between downer prescription 
drugs and prescription stimulants. Finally, the study focused exclusively on young Swiss men 
and is not representative of the general population. However, sex effects on NMUPD are well 
documented (3, 12, 15, 16, 18, 21) and the enrolment procedure in army centers enables a 
representative sample that was not exclusively composed of college or high school students. 
 
Conclusion 
This study indicated that NMUPD could be just as worrying as illicit street drug use. Indeed, 
NMUPD not only show a high and increasing occurrence in Western countries; it is also strongly 
associated with mental health issues and these associations outstripped those of mental health 
issues with illicit street drugs. The findings supported the idea that NMUPD are not “safe drugs”, 
and preventive information and interventions may focus on this class of drugs, especially for 
NMUPD that are highly addictive (opiates and sleeping pills). 
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% of users   
Illicit street drugs 
 
 
Cannabis 30.5 
 
Hallucinogens 5.0 
 
“Hard” drugs 1.2 
 
Sniffed drugs 4.2 
 
Uppers 5.6 
Non-medical use of prescription drugs  
 
Antidepressants 0.9 
 
Anxiolytics 2.6 
 
Painkillers 6.8 
 
Sleeping pills 3.0 
  Stimulants 1.9 
Table 1. Prevalence rates of illicit street drug and NMUPD use during the past 12 months 
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 Variables 
Depression   SF12 
β 
 
p 
	
β 
 
p 
Illicit street drugs 	 	 	 	 	 	 	
Cannabis .114  .000 	 -.116  .000 
Hallucinogens .111  .000 	 -.078  .000 
“Hard” drugs .125  .000 	 -.067  .000 
Sniffed drugs .080  .000 	 -.056  .000 
Uppers .107  .000 	 -.092  .000 
Non-medical use of prescription drugs 	 	  	 	   
Antidepressants .159  .000 	 -.108  .000 
Anxiolytics .162  .000 	 -.101  .000 
Painkillers .126  .000 	 -.086  .000 
Sleeping pills .163  .000 	 -.131  .000 
Stimulants .123  .000   -.076  .000 
Table 2. Simple linear regressions of mental health (depression and SF12) on illicit drugs (illicit 
street drugs and NMUPD) 
Remarks: Adjusted standardized slopes (β), β standard errors (SE) and p-value (p) are given. A Bonferroni-Holm 
correction was applied. 
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 Variables 
Depression   SF12 
β 
 
p 
	
β 
 
p 
Illicit street drugs 	 	 	 	 	 	 	
Cannabis .080  .000 	 -.093  .000 
Hallucinogens .026  .082 	 -.005  .759 
“Hard” drugs .036  .060 	 .004  .772 
Sniffed drugs .022  .098 	 -.015  .276 
Uppers .000  .994 	 -.027  .080 
Non-medical use of prescription drugs 	 	 	 	 	 	 	
Antidepressants .073  .000 	 -.052  .000 
Anxiolytics .073  .000 	 -.035  .084 
Painkillers .056  .001 	 -.040  .021 
Sleeping pills .078  .000 	 -.080  .000 
Stimulants .028  .176  -.006  .684 
Table 3. Multiple linear regressions of mental health (depression and SF12) on illicit drugs 
(illicit street drugs and NMUPD) 
Remarks: Adjusted standardized slopes (β) and p-value (p) are given. A Bonferroni-Holm correction was applied. 
 
 
 
 
 
 
	
 
 
